Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology

NCT03244020 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT03244020
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03244020 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology
Lead sponsor
Massachusetts General Hospital
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
February 16, 2018
Completion date
July 1, 2028
Enrollment
2,868 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulant-induced bleeding, bone metastases, bone sarcoma, hematoma, sarcoma, soft tissue sarcoma, venous thromboembolism